EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

COMBO ‐ RATE : An Experimentally Validated Bioinformatic Tool to Identify Promiscuous HLA Restrictions

Jessica Nevarez-Mejia iD, Raphael Trevizani, Adam Abawi, Kendall Kearns iD, Emil Johansson iD, Aaron Sutherland iD, Alba Grifoni, Ricardo da Silva Antunes iD, Alessandro Sette iD

HLA · 2026-11 · 108 (5)

DOI: 10.1111/tan.71060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HLA, online erschienen am 31.10.2026. Verfasst von Jessica Nevarez-Mejia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, California, USA. Hauptthemen laut MEDLINE: HLA Antigens, Epitopes, T-Lymphocyte, Computational Biology, Software. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Allergy and Infectious Diseases (NIAID), Swedish Research Council, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Defining HLA restriction of T cell epitopes is essential for understanding immune responses in infectious disease, autoimmunity and vaccine design. Current bioinformatic programmes, including the IEDB RATE tool, enable inference of single‐HLA restrictions from immune response data of HLA‐typed donors. However, T cell epitopes are frequently presented by multiple HLA alleles, a phenomenon termed promiscuous restriction, limiting the utility of single‐allele approaches. To address this limitation, we developed COMBO‐RATE, an extension of RATE that systematically evaluates combinations of HLA alleles to identify multi‐allelic restriction patterns. Analysis of three independent datasets spanning distinct antigen systems and different epitope discovery strategies revealed that promiscuous restriction is a near‐universal feature of immunodominant epitopes. Focusing on the 43 immunodominant CD4 + T cell epitopes identified in a B. pertussis genome‐wide screen, COMBO‐RATE outperformed conventional RATE, identifying restrictions for 35 of 43 epitopes, compared to 24 by RATE alone, and uncovered 64 additional allele restrictions, including 29 unique alleles. Experimental validation using single‐HLA transfected cell lines and antigen presentation assays confirmed COMBO‐RATE‐inferred restrictions, demonstrating that a single epitope can be independently presented by distinct HLA alleles. Overall, COMBO‐RATE provides a robust and scalable framework for defining complete HLA restriction profiles from existing population response data, with important implications for the design of vaccines requiring broad HLA coverage across genetically diverse populations. This pipeline is available as both a Python package and a user‐friendly web application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA AntigensEpitopes, T-LymphocyteComputational BiologySoftwareImmunodominant EpitopesHumansAllelesImmunoinformaticsAntigen PresentationCD4-Positive T-Lymphocytes

Substanzen

HLA AntigensEpitopes, T-LymphocyteImmunodominant Epitopes

Autor:innen und Institutionen

  • Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.
  • Fiocruz Ceará, Eusébio, Brazil.
  • Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, California, USA.

ORCID-Profile: Jessica Nevarez-Mejia, Kendall Kearns, Emil Johansson, Aaron Sutherland, Ricardo da Silva Antunes, Alessandro Sette

Förderung

  • National Institutes of Allergy and Infectious Diseases (NIAID)
  • Swedish Research Council
  • NIAID NIH HHS
  • Coalition for Epidemic Preparedness Innovations
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • Vetenskapsrådet

Zitieren

APA

Nevarez-Mejia, J., Trevizani, R., Abawi, A., Kearns, K., Johansson, E., Sutherland, A., Grifoni, A., da Silva Antunes, R., & Sette, A. (2026). COMBO ‐ RATE : An Experimentally Validated Bioinformatic Tool to Identify Promiscuous HLA Restrictions. HLA, 108(5). https://doi.org/10.1111/tan.71060

Vancouver

Nevarez-Mejia J, Trevizani R, Abawi A, Kearns K, Johansson E, Sutherland A, et al. COMBO ‐ RATE : An Experimentally Validated Bioinformatic Tool to Identify Promiscuous HLA Restrictions. HLA. 2026;108(5). doi:10.1111/tan.71060

BibTeX
@article{NevarezMejia2026,
  author = {Nevarez-Mejia, Jessica and Trevizani, Raphael and Abawi, Adam and Kearns, Kendall and Johansson, Emil and Sutherland, Aaron and Grifoni, Alba and da Silva Antunes, Ricardo and Sette, Alessandro},
  title = {COMBO ‐ RATE : An Experimentally Validated Bioinformatic Tool to Identify Promiscuous HLA Restrictions},
  journal = {HLA},
  year = {2026},
  volume = {108},
  number = {5},
  doi = {10.1111/tan.71060}
}
Kostenlos starten →